An Open-label, Single Arm, Multicenter Study on the Efficacy, Safety, and Pharmacokinetics of Leuprolide Acetate 45 mg for Injectable Suspension Controlled Release in Subjects With Central (Gonadotropin-Dependent) Precocious Puberty

Trial Profile

An Open-label, Single Arm, Multicenter Study on the Efficacy, Safety, and Pharmacokinetics of Leuprolide Acetate 45 mg for Injectable Suspension Controlled Release in Subjects With Central (Gonadotropin-Dependent) Precocious Puberty

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 18 Dec 2017

At a glance

  • Drugs Leuprorelin (Primary)
  • Indications Precocious puberty
  • Focus Therapeutic Use
  • Sponsors Tolmar
  • Most Recent Events

    • 13 Dec 2017 Planned End Date changed from 1 Dec 2017 to 1 Sep 2018.
    • 13 Dec 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Sep 2018.
    • 27 Sep 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top